Navigation Links
A hallmark for the development of testicular tumors found in the aberrant regulation of small non-coding RNA

Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona, Spain, have studied the role of a peculiar class of small non-coding RNAs that are mainly expressed in the human male germline. Whereas messenger RNAs transmit the genetic information required for protein synthesis, non-coding RNAs are functional molecules that are never translated into proteins and have important roles in diverse cellular processes. In human spermatozoa, these tiny RNAs are epigenetically regulated (by changes in the genome that do not alter the DNA sequence, such as DNA methylation) and play a critical role in male germline development. Importantly, these RNAs have also been detected in human cancer cells.

In a work published in the January 2014 issue of Epigenetics, which is entirely devoted to "Non-coding RNAs in Epigenetic Regulation," the researchers asked if in their natural functional context (the normal human testis) these small RNAs undergo aberrant epigenetic regulation, compromising their function and contributing to the transformation of cells into testicular tumor cells. The reported data suggest that epigenetic disruption of an entire small non-coding RNA pathway in human testis is indeed a hallmark for the development of testicular tumors.


Contact: Andrew Thompson
Landes Bioscience

Page: 1

Related biology news :

1. Artificial womb unlocks secrets of early embryo development
2. REST is crucial for the timing of brain development
3. Embryonic development protein active in cancer growth
4. Scientists win $2 million to study new pathway in development and maintenance of lymphoma
5. Stomata development in plants unraveled -- a valuable discovery for environmental research
6. Promising developments in early diagnosis and treatment of mesothelioma
7. Europe meets to discuss progress in energy research and development
8. Gut microbiota transplantation may prevent development of diabetes and fatty liver disease
9. New genes contributing to autism and related neurodevelopmental disorders uncovered
10. Michael J. Fox Foundation grant to Dr. Samuel Young will provide Parkinsons drug development tools
11. Navigating the IP Minefield of Human Embryonic Stem Cell Development
Post Your Comments:
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/1/2016)... June 1, 2016 Favorable Government ... Administration and Criminal Identification to Boost Global Biometrics System ... released TechSci Research report, " Global Biometrics Market ... Forecast and Opportunities, 2011 - 2021", the global biometrics ... 2021, on account of growing security concerns across various ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in ... peritoneal or pleural mesothelioma. Their findings are the subject of a new article on ... biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients that ...
(Date:6/23/2016)... Wausau, WI (PRWEB) , ... June 23, 2016 ... ... probiotic supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, ... supplements for over 35 years, is proud to add Target to its list ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology: